Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.
about
Tim-3 and Tim-4 as the potential targets for antitumor therapyBlocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune responseIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsRational combinations of immunotherapeutics that target discrete pathways.Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner.TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkersCombined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.The impact of the TIM gene family on tumor immunity and immunosuppression.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody-Mediated Operational Tolerance Induction.TIM-3, a promising target for cancer immunotherapy
P2860
Q26799502-229A6B1D-6197-4D73-8BB1-383E132E0EABQ26863081-55E15FA5-0D56-4EE0-BCD8-E31E89B6A740Q28072532-1EEAC056-9104-4138-BB85-9D55ADB3ED0AQ33606144-752C6794-27E4-4DF2-B92A-F9CD16591853Q33714165-EB77CCB0-EDEF-40D3-A6D1-B609135E4CE6Q34658452-992C89BE-816D-4A1D-93B5-E41F479FA509Q36750950-E872B981-59C0-4DD7-83AF-4B995E9DBB5DQ37211620-5F66B19F-2854-42C6-AA94-227F7A2F53C6Q37368087-B8BB231D-3C00-4F00-B26A-D9BB298E9D04Q38171224-A047FFD1-F624-4A43-B34C-5D13BB2D2DEAQ38198735-4E862071-2EB2-4819-A6DD-2790CDBE6B5CQ38374889-708D7F30-EDE8-4306-8255-84A1C06888ACQ38912251-D443BEC3-BD6D-42DB-ABFF-42C63B9805F8Q39160959-E38C5290-F572-4717-9D27-76C05F00E601Q39562562-007F96D1-C95E-48F7-83F6-1E3FF7072C0AQ41537589-9D44EAC2-A267-4EFB-A62D-CB838DF1E123Q50921102-EBDD1803-391F-4F1E-A1F1-DCAA57CAC4F3Q58558279-9406794D-8337-4936-9EAD-A4B22564C864
P2860
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Combined blockade of TIM-3 and ...... against established melanomas.
@en
Combined blockade of TIM-3 and ...... against established melanomas.
@nl
type
label
Combined blockade of TIM-3 and ...... against established melanomas.
@en
Combined blockade of TIM-3 and ...... against established melanomas.
@nl
prefLabel
Combined blockade of TIM-3 and ...... against established melanomas.
@en
Combined blockade of TIM-3 and ...... against established melanomas.
@nl
P2093
P2860
P50
P1476
Combined blockade of TIM-3 and ...... against established melanomas
@en
P2093
Hideo Yagita
Hiroko Nagao
Hirotoshi Dosaka-Akita
Hisaya Akiba
Masahisa Jinushi
P2860
P2888
P304
P356
10.1007/S00262-012-1371-9
P577
2012-11-10T00:00:00Z
P5875
P6179
1001133461